PharmaShots | Incisive News in 3 Shots

Subscribe Now

ConSynance Therapeutics

ConSynance Therapeutics’ CSTI-500 Receives the US FDA’s Rare Pediatric Disease Designation to Treat Prader-Willi Syndrome

ConSynance Therapeutics’ CSTI-500 Receives the US FDA’s Rare Pediatric Disease Designation to Treat Prader-Willi Syndrome

July 25, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us